897544-63-7

Upstream product

• 327-92-4 1,5-difluoro-2,4-dinitrobenzene 
• 110-89-4 piperidine 
• 367-81-7 2,4-dinitro-5-fluoroaniline 

Downstream Products

• 1319671-82-3 2-nitro-5-(piperidin-1-yl)benzene-1,4-diamine 
• 1319671-80-1 4-nitro-5-(piperidin-1-yl)benzene-1,2-diamine 
• 1434143-02-8 2,4-dinitro-1-(2-furyl)carboxamido-5-(piperidin-1-yl)benzene 
• 1434143-10-8 2-(2-furyl)-5-(2-methoxybenzamido)-6-(piperidin-1-yl)-1H-benzo[d]imidazole 
• 1434143-09-5 5-(2-methoxybenzamido)-6-(piperidin-1-yl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole 
• 1434143-08-4 5-benzyloxycarbonylamino-6-(piperidin-1-yl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole 
• 1434143-00-6 2,4-dinitro-1-(2-thiophenyl)carboxamido-5-(piperidin-1-yl)benzene 
• 1072919-55-1 1-cyclohexanecarboxamido-2,4-dinitro-5-piperidylbenzene 
• 1072919-59-5 5-amino-2-cyclohexyl-6-N-piperidinyl-1H-benzo[d]imidazole 

Relevant academic research and scientific papers

Benzimidazole-based antibacterial agents against Francisella tularensis

Francisella tularensis is a highly virulent pathogenic bacterium. In order to identify novel potential antibacterial agents against F. tularensis, libraries of trisubstituted benzimidazoles were screened against F. tularensis LVS strain. In a preliminary

A reverse method for diversity introduction of benzimidazole to synthesize H+/K+-ATP enzyme inhibitors

A series of 2-[(2-pyridylmethyl)sulfinyl]benzimidazole derivatives were synthesized via a solution phase synthetic route using a reversal method of diversity introduction. Using this synthetic strategy, we obtained two key intermediates (4-A and 4-B) simultaneously, which allows us to introduce diversity points onto the benzimidazole part of the final product under reliable reaction conditions to identify potent H+/K+-ATP enzyme inhibitors. Compound 14l (IC50 = 1.6 × 10-5 M) was comparable with H+/K+-ATP enzyme inhibitor in vitro.

Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents

Libraries of novel trisubstituted benzimidazoles were created through rational drug design. A good number of these benzimidazoles exhibited promising MIC values in the range of 0.5-6 μg/mL (2-15 μM) for their antibacterial activity against Mtb H37Rv strai

BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to novel benzimidazole derivatives and pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating a patient infected by Mycobacterium tuberculosis or Francisella tulerensis by ad